These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 35236274)
1. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. Saeedi M; Mehranfar F Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366 [TBL] [Abstract][Full Text] [Related]
3. Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review. Basso L; Fagundes SC; Staudt T; da Rosa K; Langaro E; Omidian H; Bertol CD CNS Neurol Disord Drug Targets; 2024; 23(9):1075-1084. PubMed ID: 37990896 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact. Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656 [TBL] [Abstract][Full Text] [Related]
7. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM. Byun J; Lee DY; Jeong CW; Kim Y; Rhee HY; Moon KW; Heo J; Hong Y; Kim WJ; Nam SJ; Choi HS; Park JI; Chun IK; Bak SH; Lee K; Byeon GH; Kim KL; Kim JA; Park YJ; Kim JH; Lee EJ; Lee SA; Kwon SO; Park SW; Kasani PH; Kim JK; Kim Y; Kim S; Jang JW Sci Rep; 2022 Mar; 12(1):4451. PubMed ID: 35292697 [TBL] [Abstract][Full Text] [Related]
8. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Ehret MJ; Chamberlin KW Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Alzheimer's disease in the long-term-care setting. Smith DA Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review. Chen Y; Lai M; Tao M Medicine (Baltimore); 2024 Apr; 103(16):e37799. PubMed ID: 38640313 [TBL] [Abstract][Full Text] [Related]
11. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine]. Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976 [TBL] [Abstract][Full Text] [Related]
12. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879 [TBL] [Abstract][Full Text] [Related]
13. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455 [TBL] [Abstract][Full Text] [Related]
14. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Jones R; Sheehan B; Phillips P; Juszczak E; Adams J; Baldwin A; Ballard C; Banerjee S; Barber B; Bentham P; Brown R; Burns A; Dening T; Findlay D; Gray R; Griffin M; Holmes C; Hughes A; Jacoby R; Johnson T; Jones R; Knapp M; Lindesay J; McKeith I; McShane R; Macharouthu A; O'Brien J; Onions C; Passmore P; Raftery J; Ritchie C; Howard R; Trials; 2009 Jul; 10():57. PubMed ID: 19630974 [TBL] [Abstract][Full Text] [Related]
15. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665 [TBL] [Abstract][Full Text] [Related]
16. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. Kim SH; Kandiah N; Hsu JL; Suthisisang C; Udommongkol C; Dash A Br J Pharmacol; 2017 Dec; 174(23):4224-4232. PubMed ID: 28901528 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease. Deardorff WJ; Grossberg GT Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. Ota H; Ogawa S; Ouchi Y; Akishita M Exp Gerontol; 2015 Dec; 72():109-16. PubMed ID: 26408226 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Noetzli M; Eap CB Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070 [TBL] [Abstract][Full Text] [Related]
20. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions]. Shimohama S Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]